|
|
Taiwan Academic Institutional Repository >
Browse by Author
|
"tien feng ming"
Showing items 1-25 of 40 (2 Page(s) Totally)
1 2 > >>
View [10|25|50] records per page
| 臺大學術典藏 |
2022-04-26T08:24:46Z |
Distinct clinico-biological features in AML patients with low allelic ratio FLT3-ITD: role of allogeneic stem cell transplantation in first remission
|
Tien, Feng-Ming; Tsai, Cheng-Hong; Huang, Sheng-Chuan; Liu, Jia-Hau; Chen, Chien-Yuan; Kuo, Yuan-Yeh; Chuang, Yi-Kuang; Tseng, Mei-Hsuan; Peng, Yen-Ling; Liu, Ming-Chih; Liu, Chia-Wen; Liao, Xiu-Wen; Lin, Liang-In; Wu, Yu-Sin; Hou, Mei-Fang; Wu, Shang-Ju; SZU-CHUN HSU; Ko, Bor-Sheng; WEN-CHIEN CHOU; MING YAO; Hou, Hsin-An; Tang, Jih-Luh; Tien, Hwei-Fang |
| 臺大學術典藏 |
2022-04-26T08:21:05Z |
Polatuzumab vedotin-based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience
|
Wang, Yu-Wen; Tsai, Xavier Cheng-Hong; Hou, Hsin-An; Tien, Feng-Ming; Liu, Jia-Hau; WEN-CHIEN CHOU; Ko, Bor-Sheng; Chen, Yu-Wen; Lin, Chien-Chin; Cheng, Chieh-Lung; Lo, Min-Yen; Lin, Yun-Chu; Lu, Li-Chun; Wu, Shang-Ju; Kuo, Sung-Hsin; Hong, Ruey-Long; Huang, Tai-Chung; MING YAO |
| 臺大學術典藏 |
2022-04-14T06:18:05Z |
Polatuzumab vedotin-based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience
|
Wang, Yu-Wen; Tsai, Xavier Cheng-Hong; Hou, Hsin-An; Tien Feng-Ming; Liu Jia-Hau; Chou, Wen-Chien; Ko, Bor-Sheng; Chen, Yu-Wen; Lin, Chien-Chin; Cheng, Chieh-Lung; Lo, Min-Yen; YUN-CHU LIN; Lu, Li-Chun; Wu, Shang-Ju; Kuo, Sung-Hsin; Hong, Ruey-Long; Huang, Tai-Chung; Ming Yao |
| 臺大學術典藏 |
2022-03-04T03:55:35Z |
Distinct clinico-biological features in AML patients with low allelic ratio FLT3-ITD: role of allogeneic stem cell transplantation in first remission
|
TIEN FENG-MING; Tsai, Cheng-Hong; Huang, Sheng-Chuan; LIU JIA-HAU; Chen, Chien-Yuan; Kuo, Yuan-Yeh; Chuang, Yi-Kuang; Tseng, Mei-Hsuan; Peng, Yen-Ling; Liu, Ming-Chih; Liu, Chia-Wen; Liao, Xiu-Wen; Lin, Liang-In; Wu, Yu-Sin; Hou, Mei-Fang; SHANG-JU WU; SZU-CHUN HSU; Ko, Bor-Sheng; Chou, Wen-Chien; MING YAO; Hou, Hsin-An; Tang, Jih-Luh; Tien, Hwei-Fang |
| 臺大學術典藏 |
2022-03-04T03:52:50Z |
Polatuzumab vedotin-based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience
|
Wang, Yu-Wen; Tsai, Xavier Cheng-Hong; Hou, Hsin-An; TIEN FENG-MING; LIU JIA-HAU; Chou, Wen-Chien; Ko, Bor-Sheng; Chen, Yu-Wen; Lin, Chien-Chin; Cheng, Chieh-Lung; Lo, Min-Yen; LIN YUN-CHU; Lu, Li-Chun; SHANG-JU WU; Kuo, Sung-Hsin; Hong, Ruey-Long; Huang, Tai-Chung; MING YAO |
| 臺大學術典藏 |
2022-01-25T05:32:21Z |
Clinical implications of sequential MRD monitoring by NGS at 2 time points after chemotherapy in patients with AML
|
CHENG-HONG TSAI; JIH-LUH TANG; Tien, Feng Ming; YUAN-YEH KUO; Wu, Dung Chi; CHIEN-CHIN LIN; Tseng, Mei Hsuan; Peng, Yen Ling; Hou, Mei Fang; Chuang, Yi Kuang; Liu, Ming Chih; CHIA-WEN LIU; MING YAO; LIANG-IN LIN; WEN-CHIEN CHOU; CHIEN-YU CHEN; HSIN-AN HOU; HWEI-FANG TIEN |
| 臺大學術典藏 |
2022-01-25T01:29:00Z |
Distinct clinico-biological features in AML patients with low allelic ratio FLT3-ITD: role of allogeneic stem cell transplantation in first remission
|
TIEN FENG-MING; Tsai, Cheng-Hong; Huang, Sheng-Chuan; LIU JIA-HAU; Chen, Chien-Yuan; Kuo, Yuan-Yeh; Chuang, Yi-Kuang; Tseng, Mei-Hsuan; Peng, Yen-Ling; Liu, Ming-Chih; Liu, Chia-Wen; Liao, Xiu-Wen; Lin, Liang-In; Wu, Yu-Sin; Hou, Mei-Fang; Wu, Shang-Ju; SZU-CHUN HSU; Ko, Bor-Sheng; Chou, Wen-Chien; MING YAO; Hou, Hsin-An; Tang, Jih-Luh; HWEI-FANG TIEN |
| 臺大學術典藏 |
2022-01-12T08:28:38Z |
Polatuzumab vedotin-based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience
|
Wang, Yu-Wen; Tsai, Xavier Cheng-Hong; Hou, Hsin-An; TIEN FENG-MING; LIU JIA-HAU; Chou, Wen-Chien; Ko, Bor-Sheng; Chen, Yu-Wen; Lin, Chien-Chin; Chieh-Lung Cheng; Lo, Min-Yen; LIN YUN-CHU; Lu, Li-Chun; Wu, Shang-Ju; Kuo, Sung-Hsin; Hong, Ruey-Long; Huang, Tai-Chung; MING YAO |
| 臺大學術典藏 |
2022-01-10T09:11:05Z |
Polatuzumab vedotin-based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience
|
Wang, Yu-Wen; Tsai, Cheng-Hong; Hou, Hsin-An; TIEN FENG-MING; LIU JIA-HAU; Chou, Wen-Chien; Ko, Bor-Sheng; Chen, Yu-Wen; Lin, Chien-Chin; Cheng, Chieh-Lung; Lo, Min-Yen; LIN YUN-CHU; Lu, Li-Chun; Wu, Shang-Ju; Kuo, Sung-Hsin; Hong, Ruey-Long; Huang, Tai-Chung; MING YAO |
| 臺大學術典藏 |
2022-01-10T08:54:12Z |
Clinical implications of sequential MRD monitoring by NGS at 2 time points after chemotherapy in patients with AML
|
CHENG-HONG TSAI; JIH-LUH TANG; Tien, Feng Ming; YUAN-YEH KUO; Wu, Dung Chi; CHIEN-CHIN LIN; Tseng, Mei Hsuan; Peng, Yen Ling; Hou, Mei Fang; Chuang, Yi Kuang; Liu, Ming Chih; CHIA-WEN LIU; MING YAO; LIANG-IN LIN; WEN-CHIEN CHOU; CHIEN-YU CHEN; HSIN-AN HOU; HWEI-FANG TIEN |
| 臺大學術典藏 |
2021-11-30T05:49:04Z |
Distinct clinico-biological features in AML patients with low allelic ratio FLT3-ITD: role of allogeneic stem cell transplantation in first remission
|
TIEN FENG-MING; Tsai, Cheng-Hong; Huang, Sheng-Chuan; LIU JIA-HAU; Chen, Chien-Yuan; Kuo, Yuan-Yeh; Chuang, Yi-Kuang; Tseng, Mei-Hsuan; Peng, Yen-Ling; Liu, Ming-Chih; Liu, Chia-Wen; Liao, Xiu-Wen; Lin, Liang-In; Wu, Yu-Sin; Hou, Mei-Fang; Wu, Shang-Ju; SZU-CHUN HSU; Ko, Bor-Sheng; Chou, Wen-Chien; MING YAO; Hou, Hsin-An; Tang, Jih-Luh; Tien, Hwei-Fang |
| 臺大學術典藏 |
2021-11-24T07:22:42Z |
Polatuzumab vedotin-based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience
|
Wang, Yu-Wen; Tsai, Xavier Cheng-Hong; Hou, Hsin-An; TIEN FENG-MING; LIU JIA-HAU; Chou, Wen-Chien; Ko, Bor-Sheng; Chen, Yu-Wen; CHIEN-CHIN LIN; Cheng, Chieh-Lung; Lo, Min-Yen; LIN YUN-CHU; Lu, Li-Chun; Wu, Shang-Ju; Kuo, Sung-Hsin; Hong, Ruey-Long; Huang, Tai-Chung; MING YAO |
| 臺大學術典藏 |
2021-11-24T07:19:27Z |
Clinical implications of sequential MRD monitoring by NGS at 2 time points after chemotherapy in patients with AML
|
Tsai, Cheng-Hong; Tang, Jih-Luh; TIEN FENG-MING; Kuo, Yuan-Yeh; Wu, Dung-Chi; CHIEN-CHIN LIN; Tseng, Mei-Hsuan; Peng, Yen-Ling; Hou, Mei-Fang; Chuang, Yi-Kuang; Liu, Ming-Chih; Liu, Chia-Wen; MING YAO; Lin, Liang-In; Chou, Wen-Chien; Chen, Chien-Yu; Hou, Hsin-An; Tien, Hwei-Fang |
| 臺大學術典藏 |
2021-11-21T23:19:44Z |
Polatuzumab vedotin–based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience
|
Wang, Yu Wen; Tsai, Xavier Cheng Hong; HSIN-AN HOU; Tien, Feng Ming; Liu, Jia Hau; WEN-CHIEN CHOU; BOR-SHENG KO; YU-WEN CHEN; CHIEN-CHIN LIN; Cheng, Chieh Lung; Lo, Min Yen; Lin, Yun Chu; Lu, Li Chun; SHANG-JU WU; SUNG-HSIN KUO; Hong, Ruey Long; TAI-CHUNG HUANG; MING YAO |
| 臺大學術典藏 |
2021-11-21T23:19:35Z |
Distinct clinico-biological features in AML patients with low allelic ratio FLT3-ITD: role of allogeneic stem cell transplantation in first remission
|
Tien, Feng Ming; CHENG-HONG TSAI; Huang, Sheng Chuan; Liu, Jia Hau; Chen, Chien-Yuan; YUAN-YEH KUO; Chuang, Yi Kuang; Tseng, Mei Hsuan; Peng, Yen Ling; Liu, Ming Chih; CHIA-WEN LIU; Liao, Xiu Wen; LIANG-IN LIN; Wu, Yu Sin; Hou, Mei Fang; SHANG-JU WU; SZU-CHUN HSU; BOR-SHENG KO; WEN-CHIEN CHOU; MING YAO; HSIN-AN HOU; JIH-LUH TANG; HWEI-FANG TIEN |
| 臺大學術典藏 |
2021-11-11T06:34:55Z |
Distinct clinico-biological features in AML patients with low allelic ratio FLT3-ITD: role of allogeneic stem cell transplantation in first remission
|
Tien, Hwei-Fang; TIEN, FENG-MING; Tsai, Cheng-Hong; Huang, Sheng-Chuan; LIU JIA-HAU; Chen, Chien-Yuan; Kuo, Yuan-Yeh; Chuang, Yi-Kuang; Tseng, Mei-Hsuan; Peng, Yen-Ling; Liu, Ming-Chih; Liu, Chia-Wen; Liao, Xiu-Wen; LIANG-IN LIN; Wu, Yu-Sin; Hou, Mei-Fang; Wu, Shang-Ju; SZU-CHUN HSU; Ko, Bor-Sheng; Chou, Wen-Chien; MING YAO; Hou, Hsin-An; Tang, Jih-Luh |
| 臺大學術典藏 |
2021-10-21T23:28:04Z |
Safety, feasibility, and effects of short-term calorie reduction during induction chemotherapy in patients with diffuse large b-cell lymphoma: A pilot study
|
CHIA-CHUN TANG; TAI-CHUNG HUANG; Tien, Feng Ming; Lin, Jing Meei; Yeh, Yi Chen; Lee, Ching Yi |
| 臺大學術典藏 |
2021-08-04T16:44:39Z |
Clinical implications of sequential MRD monitoring by NGS at 2 time points after chemotherapy in patients with AML
|
Tsai, Cheng-Hong; Tang, Jih-Luh; Tien, Feng-Ming; Kuo, Yuan-Yeh; Wu, Dung-Chi; Lin, Chien-Chin; Tseng, Mei-Hsuan; Peng, Yen-Ling; Hou, Mei-Fang; Chuang, Yi-Kuang; Liu, Ming-Chih; Liu, Chia-Wen; MING YAO; Lin, Liang-In; Chou, Wen-Chien; Chen, Chien-Yu; Hou, Hsin-An; Tien, Hwei-Fang |
| 臺大學術典藏 |
2021-07-21T07:23:28Z |
Hepatitis B reactivation among 1962 patients with hematological malignancy in Taiwan
|
Chen C.-Y.; TIEN FENG-MING; Cheng A.; Huang S.-Y.; Chou W.-C.; Yao M.; Tang J.-L.; Tien H.-F.; Sheng W.-H. |
| 臺大學術典藏 |
2021-07-21T07:23:28Z |
Clinical and microbiological characteristics of bloodstream infections among patients with haematological malignancies with and without neutropenia at a medical centre in northern Taiwan, 2008�V2013
|
Chen C.-Y.; TIEN FENG-MING; Sheng W.-H.; Huang S.-Y.; Yao M.; Tang J.-L.; Tsay W.; Tien H.-F.; Hsueh P.-R. |
| 臺大學術典藏 |
2021-07-21T07:23:27Z |
GATA2 zinc finger 1 mutations are associated with distinct clinico-biological features and outcomes different from GATA2 zinc finger 2 mutations in adult acute myeloid leukemia
|
TIEN FENG-MING; Hou H.-A.; Tsai C.-H.; Tang J.-L.; Chiu Y.-C.; Chen C.-Y.; Kuo Y.-Y.; Tseng M.-H.; Peng Y.-L.; Liu M.-C.; Liu C.-W.; Liao X.-W.; Lin L.-I.; Lin C.-T.; Wu S.-J.; Ko B.-S.; Hsu S.-C.; Huang S.-Y.; Yao M.; Chou W.-C.; Tien H.-F. |
| 臺大學術典藏 |
2021-07-21T07:23:27Z |
Hyperleukocytosis is associated with distinct genetic alterations and is an independent poor-risk factor in de novo acute myeloid leukemia patients
|
TIEN FENG-MING; Hou H.-A.; Tsai C.-H.; Tang J.-L.; Chen C.-Y.; Kuo Y.-Y.; Li C.-C.; Lin C.-T.; Yao M.; Huang S.-Y.; Ko B.-S.; Hsu S.-C.; Wu S.-J.; Tsay W.; Tseng M.-H.; Liu M.-C.; Liu C.-W.; Lin L.-I.; Chou W.-C.; Tien H.-F. |
| 臺大學術典藏 |
2021-07-21T07:23:26Z |
Concomitant WT1 mutations predict poor prognosis in acute myeloid leukemia patients with double mutant CEBPA
|
TIEN FENG-MING; Hou H.-A.; Tang J.-L.; Kuo Y.-Y.; Chen C.-Y.; Tsai C.-H.; Yao M.; Lin C.-T.; Li C.-C.; Huang S.-Y.; Ko B.-S.; Hsu S.-C.; Wu S.-J.; Liu J.-H.; Chou S.-C.; Tsay W.; Tseng M.-H.; Liu M.-C.; Liu C.-W.; Lin L.-I.; Chou W.-C.; Tien H.-F. |
| 臺大學術典藏 |
2021-07-21T07:23:26Z |
Hepatitis B reactivation during treatment of tyrosine kinase inhibitors�XExperience in 142 adult patients with chronic myeloid leukemia
|
Wang Y.-H.; Liang J.-D.; Sheng W.-H.; TIEN FENG-MING; Chen C.-Y.; Tien H.-F. |
| 臺大學術典藏 |
2021-07-21T07:23:26Z |
Incorporation of long non-coding RNA expression profile in the 2017 ELN risk classification can improve prognostic prediction of acute myeloid leukemia patients
|
Tsai C.-H.; Yao C.-Y.; TIEN FENG-MING; Tang J.-L.; Kuo Y.-Y.; Chiu Y.-C.; Lin C.-C.; Tseng M.-H.; Peng Y.-L.; Liu M.-C.; Liu C.-W.; Yao M.; Lin L.-I.; Chou W.-C.; Chen C.-Y.; Hou H.-A.; Tien H.-F. |
Showing items 1-25 of 40 (2 Page(s) Totally)
1 2 > >>
View [10|25|50] records per page
|
